How can polycythemia vera (PV) be distinguished from hereditary hemorrhagic telangiectasia (HHT) in a 54‑year‑old female?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Distinguishing PV from HHT in a 54-Year-Old Female

The key distinction is straightforward: test for JAK2 mutation and measure serum erythropoietin—PV will show JAK2 positivity (>95% of cases) with low erythropoietin, while HHT presents with secondary polycythemia from hypoxia (due to pulmonary arteriovenous malformations) with elevated erythropoietin and negative JAK2 mutation 1, 2.

Diagnostic Algorithm

Step 1: Initial Laboratory Assessment

  • JAK2 mutation testing: >95% of PV patients are JAK2-positive 1, 2
  • Serum erythropoietin level:
    • Low/suppressed in PV (autonomous RBC production)
    • Normal or elevated in HHT (appropriate response to hypoxia) 3
  • Complete blood count:
    • PV shows thrombocytosis (53%) and leukocytosis (49%) alongside erythrocytosis 1
    • HHT typically shows isolated erythrocytosis 4

Step 2: Clinical Features to Distinguish

PV-specific features 1, 2:

  • Aquagenic pruritus (33%)
  • Erythromelalgia (5.3%)
  • Splenomegaly (36%)
  • Thrombosis history (arterial 16%, venous 7% at diagnosis)
  • Visual disturbances from hyperviscosity

HHT-specific features 5, 6:

  • Recurrent epistaxis (>90% of adults)—often severe, lasting hours
  • Mucocutaneous telangiectasias (oral mucosa, lips, fingers)
  • Family history of epistaxis or telangiectasias (autosomal dominant)
  • Pulmonary arteriovenous malformations causing hypoxia 4
  • Gastrointestinal bleeding from telangiectasias

Step 3: Additional Diagnostic Studies

If JAK2-positive: Confirm PV diagnosis 7, 1

  • Bone marrow examination (morphologic confirmation advised but not mandatory)
  • Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women) required 7

If JAK2-negative with polycythemia: Investigate for HHT 5, 6

  • Screen for pulmonary AVMs (chest CT with contrast or transthoracic contrast echocardiography)
  • Examine for mucocutaneous telangiectasias
  • Obtain detailed family history
  • Consider genetic testing for HHT mutations (endoglin, ACVRL1)
  • Measure oxygen saturation and arterial blood gas

Critical Pitfalls to Avoid

Do not assume isolated erythrocytosis equals PV: When polycythemia is isolated without leukocytosis or thrombocytosis, secondary causes including HHT should be considered first 3. The presence of accompanying cytopenias strongly suggests PV over secondary causes.

Do not overlook pulmonary AVMs in HHT: These can be asymptomatic but cause right-to-left shunting leading to hypoxia-driven polycythemia 4, 6. They also carry risk of paradoxical embolism and brain abscess, requiring screening even without respiratory symptoms.

Extreme thrombocytosis (≥1000 × 10⁹/L) in PV: This can cause acquired von Willebrand disease and bleeding tendency, creating a paradoxical bleeding risk despite the thrombotic predisposition 7, 1.

Why This Distinction Matters for Outcomes

The management differs fundamentally and impacts mortality and morbidity:

  • PV requires: Phlebotomy (hematocrit target <45%), aspirin, and cytoreductive therapy for high-risk patients to prevent thrombosis 1, 2
  • HHT requires: Screening and treatment of AVMs, management of bleeding with antiangiogenic therapies, and avoidance of unnecessary antiplatelet agents that worsen bleeding 5

Misdiagnosis leads to inappropriate treatment: giving aspirin to an HHT patient worsens bleeding, while missing PV diagnosis leaves thrombotic risk unaddressed (16% arterial thrombosis rate) 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.